Welcome to our dedicated page for Alterity Therapeutics SEC filings (Ticker: ATHE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alterity Therapeutics Limited filings document a foreign private issuer and development-stage biotechnology company reporting through Form 6-K and incorporated reports tied to Form S-8 and Form F-3 registration statements. The filings record ATH434 and MSA development updates, bioMUSE biomarker publications, FDA meeting communications, medical conference presentations, and Appendix 4C quarterly cash flow and activity reports.
Other disclosures cover shareholder meeting and proxy materials, substantial holding notices, share consolidation or split notices, board and governance changes, and capital-structure matters for securities traded as ASX: ATH and NASDAQ: ATHE.
Alterity Therapeutics, a clinical stage biotechnology company, announced that Chief Executive Officer David Stamler, M.D., will participate in the virtual BTIG Biotechnology Conference 2026 on 28-29 July 2026, where he will host 1-on-1 meetings with investors in the United States.
The company develops disease modifying therapies for neurodegenerative diseases, focusing on Multiple System Atrophy and related Parkinsonian disorders. Alterity is preparing a Phase 3 pivotal trial in MSA for its lead asset ATH434, which has shown clinically meaningful efficacy and positive data in Phase 2 clinical studies.
Alterity Therapeutics Limited reports receiving an R&D tax refund of A$3,982,992 for the 2025 financial year, including A$43,117 in interest, under the Australian Government’s R&D tax incentive program.
The incentive provides a refundable tax offset of up to 43.5% for eligible R&D activities. Alterity states that this cash refund will provide important funding to continue developing its clinical programs, including its lead candidate ATH434 for Multiple System Atrophy, where it has completed Phase 2 trials and is preparing a Phase 3 pivotal study.
Alterity Therapeutics reported that official FDA End-of-Phase 2 meeting minutes for ATH434 in Multiple System Atrophy confirm the planned registrational Phase 3 program and a clear path toward a potential New Drug Application. The FDA agreed that a single pivotal Phase 3 trial, supported by confirmatory evidence, could support approval of ATH434 for MSA.
The Phase 3 study is expected to enroll about 200 patients, randomized 1:1 to ATH434 50 mg or placebo twice daily for 12 months, with the 11‑item UMSARS Part I as the primary endpoint and several functional secondary endpoints. Trial activities are described as on track to start by year-end 2026, with an open-label extension planned and Phase 2 data intended to serve as confirmatory evidence.
ALTERITY THERAPEUTICS LTD director Julian Michael Babarczy, through Vaucluse Investment Holdings Pty Ltd <Jigsaw Investment A/C>, received a grant of unlisted options on June 15, 2026. The award covers 2,000,000 options, each exercisable into one ordinary share at an exercise price of 1.0000 per share, expiring on June 15, 2031. This is a compensation-related acquisition of derivative securities, not an open-market share purchase or sale, and leaves 2,000,000 options held indirectly following the transaction.
ALTERITY THERAPEUTICS LTD director Lawrence Bernard Gozlan, through Montoya Pty Ltd <Buttercup A/C>, received a grant of derivative securities. The award consists of 1,000,000 listed options, each exercisable into one ordinary share at an exercise price of $1.0000 per share.
The options were granted on 15 June 2026 and expire on 15 June 2031. Following this grant, the indirect holdings reported in this listed option position total 1,000,000 options.